cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.4052957
title: Dataset for the paper "Ripa M, Di Felice LJ, Giampietro M (2021). The energy metabolism of post-industrial economies. A framework to account for externalization across scales. Energy, 214." https://doi.org/10.1016/j.energy.2020.118943

description: This repository contains the data needed to reproduce the results in: Ripa M, Di Felice LJ, Giampietro M (2021). The energy metabolism of post-industrial economies. A framework to account for externalization across scales. Energy, 214." https://doi.org/10.1016/j.energy.2020.118943 The dataset was also used for a case study in "Di Felice L., Dunlop T., Giampietro M., Kovacic Z., Renner A., Ripa M., Velasco-Fernández R. – Report on the Quality Check of the Robustness of the Narrative behind Energy Directives. MAGIC (H2020–GA 689669) Project Deliverable 5.4, 30 November 2018". (link: https://magic-nexus.eu/documents/d54-report-narratives-behind-energy-directives). Sources of data are specified in the dataset (under tab "References")
DOI: 10.6084/m9.figshare.13153214
title: Supplementary Material for: <b><i>CYP24A1</i></b> rs1570669 Variant Has a Protective Effect against Tumors of the Urinary System

description: <b><i>Background:</i></b> Common malignant tumors of the urinary system include renal cell carcinoma, bladder carcinoma, and prostate cancer. The research on the <i>CYP24A1</i> gene for prostate cancer is mainly concentrated in European and American populations, and there are few studies in the Chinese population. Therefore, we selected bladder cancer, prostate cancer, and renal cancer as the research objects to explore the influence of <i>CYP24A1</i> on the genetic susceptibility of urinary system tumors. <b><i>Materials and Methods:</i></b> rs6068816, rs2296241, rs2762934, and rs1570669 in 529 patients and 523 controls were genotyped via the Agena MassARRAY. Logistic regression analysis was used to evaluate the odd ratios (ORs) and 95% confidence intervals (CIs) of two SNPs with susceptibility of urinary system cancer. Database predicts the expression of the <i>CYP24A1</i> gene in urinary system cancer. <b><i>Results:</i></b> Individuals with the AG genotype of <i>CYP24A1</i> rs1570669 has a 28% lower risk of developing urinary system tumors (OR = 0.72, 95% CI: 0.56–1.13, <i>p</i> = 0.016) and has a 31% lower risk of developing renal cancer (OR = 0.69, 95% CI: 0.51–0.92, <i>p</i> = 0.012). <b><i>Conclusions:</i></b> <i>CYP24A1</i> rs1570669 may play an important role in the susceptibility of tumors of the urinary system and renal cancer.
DOI: 10.6084/m9.figshare.13153262.v1
title: PROTOCOLO MEDIGES V 2.0 (2017).pdf

description: Study protocol
DOI: 10.6084/m9.figshare.13153262
title: PROTOCOLO MEDIGES V 2.0 (2017).pdf

description: Study protocol
DOI: 10.6084/m9.figshare.13153190
title: Table S1.docx

description: Table S1. Cosine analysis fit statistics for each participant R<sup>2</sup> (<i>p</i>-value). Values in bold denote significance (<i>p </i>&lt; 0.05)
DOI: 10.6084/m9.figshare.13153190.v1
title: Table S1.docx

description: Table S1. Cosine analysis fit statistics for each participant R<sup>2</sup> (<i>p</i>-value). Values in bold denote significance (<i>p </i>&lt; 0.05)
DOI: 10.5281/zenodo.4146916
title: Supporting_information_of_Evalution of the High-degree Gravity Model at the Eastern Margin of Tibetan Plateau

description: dataset for the paper "Evalution of the High-degree Gravity Model at the Eastern Margin of Tibetan Plateau"
DOI: 10.5281/zenodo.4146915
title: Supporting_information_of_Evalution of the High-degree Gravity Model at the Eastern Margin of Tibetan Plateau

description: dataset for the paper "Evalution of the High-degree Gravity Model at the Eastern Margin of Tibetan Plateau"
DOI: 10.6084/m9.figshare.13153280
title: Calculatins - Mortality displacement: Vulnerable “dry tinder” elders in Sweden prior to COVID-19 may partially account for excess deaths

description: All calculations related to the paper: Mortality displacement: Vulnerable “dry tinder” elders in Sweden prior to COVID-19 may partially account for excess deaths
DOI: 10.6084/m9.figshare.13153280.v1
title: Calculatins - Mortality displacement: Vulnerable “dry tinder” elders in Sweden prior to COVID-19 may partially account for excess deaths

description: All calculations related to the paper: Mortality displacement: Vulnerable “dry tinder” elders in Sweden prior to COVID-19 may partially account for excess deaths
DOI: 10.5281/zenodo.4146876
title: Dataset of manuscript "Automatic fault mapping in remote optical images and topographic data with deep learning", submitted to Journal of Geophysical Research - Solid Earth on October 28, 2020

description: The dataset includes:<br> - the image and topographic data used in the study<br> - the ground truth used in the study<br> - the parameters of the model MRef developed in the study<br> - the Supplementary documents and figures discussed in the paper
description: Contact : Laboratoire Géoazur 250 rue Albert Einstein - 06560 Valbonne +33 4 83 61 86 35 Emails : matteo@geoazur.unice.fr, lionelmatteo93@gmail.com manighetti@geoazur.unice.fr
DOI: 10.5519/qd.m8574kdu
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (13 records)
DOI: 10.5519/qd.i4ybbzux
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (9 records)
DOI: 10.6084/m9.figshare.13153316
title: Supplementary Material for: Effect of Combined Statin and Antihypertensive Therapy in Patients with Hypertension: A Systematic Review and Meta-Analysis

description: <b><i>Introduction:</i></b> This meta-analysis aimed to explore the preventive effects of combined statin and antihypertensive therapy on major cardiovascular outcomes in patients with hypertension. <b><i>Methods:</i></b> PubMed, Embase, and the Cochrane Library databases and reference lists of published studies were systematically searched throughout October 9, 2019. Studies designed as randomized controlled trials and investigating the effects of combined statin and antihypertensive therapy versus antihypertensive therapy alone were included. Data abstraction and quality of included studies were assessed by 2 independent authors. The summary results were calculated using relative risks (RRs) with 95% CIs employing a random-effects model. <b><i>Results:</i></b> A total of 8 randomized controlled trials including 38,618 patients were finally enrolled. The summary RRs indicated that the combined therapy significantly reduced the risk of major adverse cardiovascular events compared with antihypertensive therapy alone (RR 0.79; 95% CI 0.71–0.88; <i>p</i> &lt; 0.001). Furthermore, the patients in the combined therapy group also experienced less myocardial infarction (RR 0.67; 95% CI 0.53–0.84; <i>p</i> = 0.001) and stroke risks (RR 0.82; 95% CI 0.72–0.94; <i>p</i> = 0.005), while no significant difference was observed between combined therapy and antihypertensive therapy alone regarding cardiac death (RR 0.96; 95% CI 0.84–1.08; <i>p</i> = 0.465) and all-cause mortality (RR 0.95; 95% CI 0.86–1.04; <i>p</i> = 0.277). <b><i>Conclusion:</i></b> These findings suggested that combined statin and antihypertensive therapy was associated with more cardiovascular benefits compared with antihypertensive therapy alone.
DOI: 10.6084/m9.figshare.13153316.v1
title: Supplementary Material for: Effect of Combined Statin and Antihypertensive Therapy in Patients with Hypertension: A Systematic Review and Meta-Analysis

description: <b><i>Introduction:</i></b> This meta-analysis aimed to explore the preventive effects of combined statin and antihypertensive therapy on major cardiovascular outcomes in patients with hypertension. <b><i>Methods:</i></b> PubMed, Embase, and the Cochrane Library databases and reference lists of published studies were systematically searched throughout October 9, 2019. Studies designed as randomized controlled trials and investigating the effects of combined statin and antihypertensive therapy versus antihypertensive therapy alone were included. Data abstraction and quality of included studies were assessed by 2 independent authors. The summary results were calculated using relative risks (RRs) with 95% CIs employing a random-effects model. <b><i>Results:</i></b> A total of 8 randomized controlled trials including 38,618 patients were finally enrolled. The summary RRs indicated that the combined therapy significantly reduced the risk of major adverse cardiovascular events compared with antihypertensive therapy alone (RR 0.79; 95% CI 0.71–0.88; <i>p</i> &lt; 0.001). Furthermore, the patients in the combined therapy group also experienced less myocardial infarction (RR 0.67; 95% CI 0.53–0.84; <i>p</i> = 0.001) and stroke risks (RR 0.82; 95% CI 0.72–0.94; <i>p</i> = 0.005), while no significant difference was observed between combined therapy and antihypertensive therapy alone regarding cardiac death (RR 0.96; 95% CI 0.84–1.08; <i>p</i> = 0.465) and all-cause mortality (RR 0.95; 95% CI 0.86–1.04; <i>p</i> = 0.277). <b><i>Conclusion:</i></b> These findings suggested that combined statin and antihypertensive therapy was associated with more cardiovascular benefits compared with antihypertensive therapy alone.
DOI: 10.6084/m9.figshare.13153337
title: Supplementary Material for: The Degree of the Predischarge Pulmonary Congestion in Patients Hospitalized for Worsening Heart Failure Predicts Readmission and Mortality

description: <b><i>Background:</i></b> Prediction of readmission and death after hospitalization for heart failure (HF) is an unmet need. <b><i>Aim:</i></b> We evaluated the ability of clinical parameters, NT-proBNP level and noninvasive lung impedance (LI), to predict time to readmission (TTR) and time to death (TTD). <b><i>Methods and Results:</i></b> The present study is a post hoc analysis of the IMPEDANCE-HF extended trial comprising 290 patients with LVEF ≤45% and New York Heart Association functional class II–IV, randomized 1:1 to LI-guided or conventional therapy. Of all patients, 206 were admitted 766 times for HF during a follow-up of 57 ± 39 months. The normal LI (NLI), representing the “dry” lung status, was calculated for each patient at study entry. The current degree of pulmonary congestion (PC) compared with its dry status was represented by ΔLIR = ([measured LI/NLI] – 1) × 100%. Twenty-six parameters recorded during HF admission were used to predict TTR and TTD. To determine the parameter which mainly impacted TTR and TTD, variables were standardized, and effect size (ES) was calculated. Multivariate analysis by the Andersen-Gill model demonstrated that ΔLIR<sub>admission</sub> (ES = 0.72), ΔLIR<sub>discharge</sub> (ES = –3.14), group assignment (ES = 0.2), maximal troponin during HF admission (ES = 0.19), LVEF related to admission (ES = –0.22) and arterial hypertension (ES = 0.12) are independent predictors of TTR (<i>p</i> &lt; 0.01, <i>χ</i><sup>2</sup> = 1,206). Analysis of ES showed that residual PC assessed by ∆LIR<sub>discharge</sub> was the most prominent predictor of TTR. One percent improvement in predischarge PC, assessed by ∆LIR<sub>discharge</sub>, was associated with a likelihood of TTR increase by 14% (hazard ratio [HR] 1.14, 95% confidence interval [CI] 1.13–1.15, <i>p</i> &lt; 0.01) and TTD increase by 8% (HR 1.08, 95% CI 1.07–1.09, <i>p</i> &lt; 0.01). <b><i>Conclusion:</i></b> The degree of predischarge PC assessed by ∆LIR is the most dominant predictor of TTR and TTD.
DOI: 10.6084/m9.figshare.13153337.v1
title: Supplementary Material for: The Degree of the Predischarge Pulmonary Congestion in Patients Hospitalized for Worsening Heart Failure Predicts Readmission and Mortality

description: <b><i>Background:</i></b> Prediction of readmission and death after hospitalization for heart failure (HF) is an unmet need. <b><i>Aim:</i></b> We evaluated the ability of clinical parameters, NT-proBNP level and noninvasive lung impedance (LI), to predict time to readmission (TTR) and time to death (TTD). <b><i>Methods and Results:</i></b> The present study is a post hoc analysis of the IMPEDANCE-HF extended trial comprising 290 patients with LVEF ≤45% and New York Heart Association functional class II–IV, randomized 1:1 to LI-guided or conventional therapy. Of all patients, 206 were admitted 766 times for HF during a follow-up of 57 ± 39 months. The normal LI (NLI), representing the “dry” lung status, was calculated for each patient at study entry. The current degree of pulmonary congestion (PC) compared with its dry status was represented by ΔLIR = ([measured LI/NLI] – 1) × 100%. Twenty-six parameters recorded during HF admission were used to predict TTR and TTD. To determine the parameter which mainly impacted TTR and TTD, variables were standardized, and effect size (ES) was calculated. Multivariate analysis by the Andersen-Gill model demonstrated that ΔLIR<sub>admission</sub> (ES = 0.72), ΔLIR<sub>discharge</sub> (ES = –3.14), group assignment (ES = 0.2), maximal troponin during HF admission (ES = 0.19), LVEF related to admission (ES = –0.22) and arterial hypertension (ES = 0.12) are independent predictors of TTR (<i>p</i> &lt; 0.01, <i>χ</i><sup>2</sup> = 1,206). Analysis of ES showed that residual PC assessed by ∆LIR<sub>discharge</sub> was the most prominent predictor of TTR. One percent improvement in predischarge PC, assessed by ∆LIR<sub>discharge</sub>, was associated with a likelihood of TTR increase by 14% (hazard ratio [HR] 1.14, 95% confidence interval [CI] 1.13–1.15, <i>p</i> &lt; 0.01) and TTD increase by 8% (HR 1.08, 95% CI 1.07–1.09, <i>p</i> &lt; 0.01). <b><i>Conclusion:</i></b> The degree of predischarge PC assessed by ∆LIR is the most dominant predictor of TTR and TTD.
DOI: 10.6084/m9.figshare.13153292
title: Supplementary Material for: A Novel Mutation in Insulin-Like Growth Factor 1 Receptor (c.641-2A&gt;G) Is Associated with Impaired Growth, Hypoglycemia, and Modified Immune Phenotypes

description: <b><i>Introduction:</i></b> Insulin-like growth factor 1 receptor (IGF1R) mutations lead to systemic disturbances in growth and glucose homeostasis due to widespread IGF1R expression throughout the body. IGF1R is expressed by innate and adaptive immune cells, facilitating their development and exerting immunomodulatory roles in the periphery. <b><i>Case Presentation:</i></b> We report on a family presenting with a novel heterozygous <i>IGF1R</i> mutation with characterization of the mutation, IGF1R expression, and immune phenotyping. Twin probands presented clinically with short stature and hypoglycemia. Variable phenotypic expression was seen in 2 other family members carrying the <i>IGF1R</i> mutation. The probands were treated with exogenous growth hormone therapy and dietary cornstarch, improving linear growth and reducing hypoglycemic events. <i>IGF1R</i> c.641-2A&gt;G caused abnormal mRNA splicing and premature protein termination. Flow cytometric immunophenotyping demonstrated lower IGF1R on peripheral blood mononuclear cells from <i>IGF1R</i> c.641-2A&gt;G subjects. This alteration was associated with reduced levels of T-helper 17 cells and a higher percentage of T-helper 1 cells compared to controls, suggesting decreased IGF1R expression may affect CD4<sup>+</sup> Th-cell lineage commitment. <b><i>Discussion:</i></b> Collectively, these data suggest a novel loss-of-function mutation (c.641-2A&gt;G) leads to aberrant mRNA splicing and IGF1R expression resulting in hypoglycemia, growth restriction, and altered immune phenotypes.
DOI: 10.6084/m9.figshare.13153292.v1
title: Supplementary Material for: A Novel Mutation in Insulin-Like Growth Factor 1 Receptor (c.641-2A&gt;G) Is Associated with Impaired Growth, Hypoglycemia, and Modified Immune Phenotypes

description: <b><i>Introduction:</i></b> Insulin-like growth factor 1 receptor (IGF1R) mutations lead to systemic disturbances in growth and glucose homeostasis due to widespread IGF1R expression throughout the body. IGF1R is expressed by innate and adaptive immune cells, facilitating their development and exerting immunomodulatory roles in the periphery. <b><i>Case Presentation:</i></b> We report on a family presenting with a novel heterozygous <i>IGF1R</i> mutation with characterization of the mutation, IGF1R expression, and immune phenotyping. Twin probands presented clinically with short stature and hypoglycemia. Variable phenotypic expression was seen in 2 other family members carrying the <i>IGF1R</i> mutation. The probands were treated with exogenous growth hormone therapy and dietary cornstarch, improving linear growth and reducing hypoglycemic events. <i>IGF1R</i> c.641-2A&gt;G caused abnormal mRNA splicing and premature protein termination. Flow cytometric immunophenotyping demonstrated lower IGF1R on peripheral blood mononuclear cells from <i>IGF1R</i> c.641-2A&gt;G subjects. This alteration was associated with reduced levels of T-helper 17 cells and a higher percentage of T-helper 1 cells compared to controls, suggesting decreased IGF1R expression may affect CD4<sup>+</sup> Th-cell lineage commitment. <b><i>Discussion:</i></b> Collectively, these data suggest a novel loss-of-function mutation (c.641-2A&gt;G) leads to aberrant mRNA splicing and IGF1R expression resulting in hypoglycemia, growth restriction, and altered immune phenotypes.
DOI: 10.6084/m9.figshare.13153283
title: Supplementary Material for: High-Dose Erythropoietin in Extremely Low Gestational Age Neonates Does Not Alter Risk of Retinopathy of Prematurity

description: <b><i>Introduction:</i></b> The Preterm Erythropoietin (Epo) Neuroprotection (PENUT) Trial sought to determine the safety and efficacy of early high-dose Epo as a potential neuroprotective treatment. We hypothesized that Epo would not increase the incidence or severity of retinopathy of prematurity (ROP). <b><i>Methods:</i></b> A total of 941 infants born between 24–0/7 and 27–6/7 weeks’ gestation were randomized to 1,000 U/kg Epo or placebo intravenously for 6 doses, followed by subcutaneous or sham injections of 400 U/kg Epo 3 times a week through 32 weeks post-menstrual age. In this secondary analysis of PENUT trial data, survivors were evaluated for ROP. A modified intention-to-treat approach was used to compare treatment groups. In addition, risk factors for ROP were evaluated using regression methods that account for multiples and allow for adjustment for treatment and gestational age at birth. <b><i>Results:</i></b> Of 845 subjects who underwent ROP examination, 503 were diagnosed with ROP with similar incidence and severity between treatment groups. Gestational age at birth, birth weight, prenatal magnesium sulfate, maternal antibiotic exposure, and presence of heart murmur at 2 weeks predicted the development of any ROP, while being on high-frequency oscillator or high-frequency jet ventilation (HFOV/HFJV) at 2 weeks predicted severe ROP. <b><i>Conclusion:</i></b> Early high-dose Epo followed by maintenance dosing through 32 weeks does not increase the risk of any or severe ROP in extremely low gestational age neonates. Gestational age, birth weight, maternal treatment with magnesium sulfate, antibiotic use during pregnancy, and presence of a heart murmur at 2 weeks were associated with increased risk of any ROP. Treatment with HFOV/HFJV was associated with an increased risk of severe ROP.
DOI: 10.6084/m9.figshare.13153277
title: Supplementary Material for: Intravenous Edaravone plus Therapeutic Hypothermia Offers Limited Neuroprotection in the Hypoxic-Ischaemic Newborn Piglet

description: <b><i>Background:</i></b> Therapeutic hypothermia (TH) is a standard therapy for neonatal hypoxic-ischaemic encephalopathy. One potential additional therapy is the free radical scavenger edaravone (EV; 3-methyl-1-phenyl-2-pyrazolin-5-one). <b><i>Objectives and Methods:</i></b> This study aimed to compare the neuroprotective effects of edaravone plus therapeutic hypothermia (TH + EV) with those of TH alone after a hypoxic-ischaemic insult in the newborn piglet. Anaesthetized piglets were subjected to 40 min of hypoxia (3–5% inspired oxygen), and cerebral ischaemia was assessed using cerebral blood volume. Body temperature was maintained at 39.0 ± 0.5°C in the normothermia group (NT, <i>n</i> = 8) and at 33.5 ± 0.5°C (24 h after the insult) in the TH (<i>n</i> = 7) and TH + EV (3 mg/kg intravenous every 12 h for 3 days after the insult; <i>n</i> = 6) groups under mechanical ventilation. <b><i>Results:</i></b> Five days after the insult, the mean (standard deviation) neurological scores were 10.9 (5.7) in the NT group, 17.0 (0.4) in the TH group (<i>p</i> = 0.025 vs. NT), and 15.0 (3.9) in the TH + EV group. The histopathological score of the TH + EV group showed no significant improvement compared with that of the other groups. <b><i>Conclusion:</i></b> TH + EV had no additive neuroprotective effects after hypoxia-ischaemia in neurological and histopathological assessments.
DOI: 10.21227/469b-3f34
title: Model 2.9

description: Model 2.9 Clustered-meter average monthly ratios Monthly (kWh) consumption clustering: 1. Twelve clustering models (one per month of signup): Spectral Clustering2. Clustering using (daily kWh) consumption extracted features. Cluster count set to 4 (empirically better than the 5 or 6 suggested by the elbow distortion method). Forecasting for a meter: Using the mean monthly consumption + in-cluster month-to-month ratios. Clustering Features (170) from weekend/weekday and full series:- Statistical: median, variance, quantiles, ...- Time-series: autocorrelations, trends, seasonalities, ... Post-processing of clustering data: Standardization. Time-series preprocessing:- Hourly resampling -&gt; 8h moving average -&gt; daily resampling.
DOI: 10.6084/m9.figshare.7165531
title: EverDrill borehole thermometry datasets

description: Datasets from the EverDrill project, measuring ice temperatures within Khumbu Glacier, Nepal, as published in Miles et al. (2018) entitled: <i>'Polythermal structure of a Himalayan debris-covered glacier revealed by borehole thermometry'</i>. Please cite this paper if using this data: <br><i>Miles, K.E., Hubbard, B., Quincey, D.J., Miles, E.S., Sherpa, T.C., Rowan, A.V. and Doyle, S.H. (2018), Polythermal structure of a Himalayan debris-covered glacier revealed by borehole thermometry, Scientific Reports, 8, 16825, </i>https://doi.org/10.1038/s41598-018-34327-5<i><br></i><i></i><br><b>Contents</b>1. <b>ED_Site1_Sensors_2017</b>: Instrumented borehole location at Site 1 and thermistor sensor depths<br>2. <b>ED_Site2_Sensors_2017</b>: Instrumented borehole location at Site 2 and thermistor sensor depths<br>3. <b>ED_Site3_Sensors_2017</b>: Instrumented borehole location at Site 3 and thermistor sensor depths<br>4. <b>ED_Site1_ThermistorRecords_2017</b>: Temperature time series from the Site 1 thermistor string at 10 min intervals (10 to 27 May 2017)<br>5. <b>ED_Site2_ThermistorRecords_2017</b>: Temperature time series from the Site 2 thermistor string at 10 min intervals (17 May to 20 October 2017)<br>6. <b>ED_Site3_ThermistorRecords_2017</b>: Temperature time series from the Site 3 thermistor string at 10 min intervals (23 May to 25 October 2017)